Helix BioMedix, Inc. (HXBM)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Helix BioMedix, Inc. (HXBM) trades at $1.79 with AI Score 50/100 (Grade B). Helix BioMedix, Inc. is a specialty dermatology company focused on developing and commercializing bioactive peptides for skin health. Market cap: $402,227, Sector: Healthcare.
Last analyzed: Mar 15, 2026Analyst Coverage for HXBM: HXBM does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates HXBM against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
HXBM: 2/6 perspectives are bullish. Dominant signal: Izzy Englander bullish.
Helix BioMedix, Inc. (HXBM) Healthcare & Pipeline Overview
Helix BioMedix, Inc., founded in 1988, specializes in bioactive peptides for dermatology and consumer skin health. With a focus on anti-infective and anti-inflammatory applications, the company develops treatments for skin and wound infections, operating within the competitive biotechnology sector and out-licensing its proprietary peptides.
What Is the Investment Thesis for HXBM?
Helix BioMedix, Inc. presents a focused investment opportunity within the specialty dermatology sector. The company's emphasis on bioactive peptides for skin health, particularly anti-infective and anti-inflammatory applications, addresses a growing market need. A key value driver is the company's ability to develop and out-license proprietary peptides, creating multiple revenue streams. With a gross margin of 99.2%, the company demonstrates strong potential for profitability. However, the negative P/E ratio of -0.23 and a profit margin of -122.1% indicate current financial challenges. The company’s small size and OTC market listing introduce liquidity and regulatory risks. Potential growth catalysts include successful commercialization of new peptide-based products and expansion of out-licensing agreements. Investors should closely monitor the company's ability to achieve profitability and manage its operational costs.
Based on FMP financials and quantitative analysis
HXBM Key Highlights
- Gross margin of 99.2% indicates strong pricing power and efficient production of bioactive peptides.
- Negative P/E ratio of -0.23 reflects current losses and challenges in achieving profitability.
- Profit margin of -122.1% highlights significant operational costs relative to revenue.
- Market capitalization of $0.00B indicates the company's small size and potential for high volatility.
- Beta of 0.52 suggests lower volatility compared to the overall market.
Who Are HXBM's Competitors?
Who Are HXBM's Competitors?
HXBM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BPTH Bio-Path Holdings, Inc. | $0.06 | +8.50% | 561K | 44 |
| EMMA Emmaus Life Sciences, Inc. | $0.01 | +0.00% | 702K | — |
| NSTM NovelStem International Corp. | $0.01 | +0.00% | 493K | 47 |
| SNDX Syndax Pharmaceuticals, Inc. | $17.34 | -3.77% | 2B | 79 |
| ANAB AnaptysBio, Inc. | $57.69 | +1.54% | $2.49B | 79 |
| XFOR X4 Pharmaceuticals, Inc. | $3.82 | -0.26% | 361M | 76 |
| ABCL AbCellera Biologics Inc. | $4.96 | +3.01% | 2B | 76 |
| TLX Telix Pharmaceuticals Limited | $11.26 | +2.36% | 4B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are HXBM's Key Strengths?
- Proprietary peptide technologies.
- High gross margin (99.2%).
- Focus on a growing market for skin health solutions.
What Are HXBM's Weaknesses?
- Negative profit margin (-122.1%).
- Small market capitalization ($0.00B).
- Limited number of employees (8).
What Could Drive HXBM Stock Higher?
- Potential FDA approval of new peptide-based treatments.
- Expansion of out-licensing agreements with pharmaceutical companies.
- Positive results from clinical trials of new products.
What Are the Key Risks for HXBM?
- Failure to obtain regulatory approvals for new products.
- Competition from larger pharmaceutical and skincare companies.
- Limited financial resources and potential need for additional funding.
- Dependence on key personnel and potential loss of expertise.
What Are the Growth Opportunities for HXBM?
- Expansion of Out-Licensing Agreements: Helix BioMedix can drive growth by expanding its out-licensing agreements with other pharmaceutical and skincare companies. The market for licensed peptide technologies is estimated to reach $5 billion by 2028. By securing new partnerships, Helix BioMedix can generate additional revenue streams and leverage its research and development investments. This strategy allows the company to focus on its core competencies while benefiting from the commercialization efforts of its partners.
- Development of Novel Peptide-Based Products: Investing in research and development to create new peptide-based products for various skin conditions represents a significant growth opportunity. The global dermatology market is projected to reach $45 billion by 2027. By developing innovative treatments for conditions such as acne, eczema, and psoriasis, Helix BioMedix can capture a larger share of this market. Successful clinical trials and regulatory approvals are critical for this growth strategy.
- Strategic Partnerships with Dermatology Clinics: Forming strategic partnerships with dermatology clinics and healthcare providers can enhance Helix BioMedix's market reach and distribution capabilities. The market for professional skincare products is estimated at $15 billion annually. By collaborating with clinics, Helix BioMedix can gain access to a wider customer base and increase brand awareness. These partnerships can also facilitate clinical studies and gather real-world data on product efficacy.
- Geographic Expansion into International Markets: Expanding into international markets, particularly Europe and Asia, presents a significant growth opportunity for Helix BioMedix. The global skincare market is projected to reach $180 billion by 2025, with Asia being the fastest-growing region. By adapting its products to meet the specific needs of different markets and establishing distribution networks, Helix BioMedix can diversify its revenue streams and reduce its reliance on the US market.
- Focus on Preventative Skincare Solutions: Developing preventative skincare solutions targeting specific demographics, such as anti-aging or sun protection products, can drive growth and increase customer loyalty. The global anti-aging market is projected to reach $100 billion by 2028. By creating innovative products that address the needs of these segments, Helix BioMedix can expand its product portfolio and attract new customers. This strategy aligns with the growing consumer focus on proactive health and wellness.
What Opportunities Does HXBM Have?
- Expansion of out-licensing agreements.
- Development of new peptide-based products.
- Geographic expansion into international markets.
What Threats Does HXBM Face?
- Competition from larger pharmaceutical and skincare companies.
- Regulatory hurdles and clinical trial risks.
- Economic downturns affecting consumer spending on skincare products.
What Are HXBM's Competitive Advantages?
- Proprietary peptide technologies protected by patents.
- Specialized expertise in bioactive peptide development.
- Established relationships with dermatology clinics and healthcare providers.
What Does HXBM Do?
Helix BioMedix, Inc., established in 1988 and headquartered in Bothell, Washington, is a specialty dermatology and consumer products skin health company operating in the United States. The company focuses on the development and commercialization of bioactive peptides designed for various applications in skin health. Its core business revolves around creating anti-infective, anti-fungal, and anti-inflammatory peptides. These peptides are primarily used in treatments for skin and wound infections. A key area of focus is the prevention of staphylococcus aureus infections, addressing a significant concern in healthcare. In addition to developing and commercializing its own products, Helix BioMedix also out-licenses its proprietary peptides to other entities, expanding its reach and potential revenue streams. This out-licensing strategy allows the company to leverage its research and development efforts by partnering with other organizations. The company's focus on bioactive peptides positions it within the broader biotechnology and dermatology markets, catering to the increasing demand for advanced skin health solutions. With a small team of 8 employees, Helix BioMedix operates with a lean structure, emphasizing innovation and strategic partnerships.
What Products and Services Does HXBM Offer?
- Develops bioactive peptides for skin health.
- Commercializes anti-infective peptides for skin infections.
- Creates anti-fungal peptides for fungal skin conditions.
- Produces anti-inflammatory peptides for skin inflammation.
- Develops treatments for skin and wound infections.
- Focuses on preventing staphylococcus aureus infections.
- Out-licenses proprietary peptides to other companies.
How Does HXBM Make Money?
- Develops and sells bioactive peptides for skin health applications.
- Generates revenue through direct sales of its products.
- Out-licenses its proprietary peptide technologies to other companies for royalties and licensing fees.
What Industry Does HXBM Operate In?
Helix BioMedix operates within the biotechnology and dermatology sectors, which are characterized by rapid innovation and increasing demand for advanced skin health solutions. The market for bioactive peptides is growing, driven by the need for effective treatments for skin infections and inflammatory conditions. Competition includes companies like Bio Path Holdings (BPTH), which focuses on cancer therapeutics, and Emmaus Life Sciences (EMMA), which addresses sickle cell disease. Helix BioMedix differentiates itself through its specialization in dermatology and its out-licensing strategy. The overall biotechnology sector is projected to grow, driven by advancements in research and development and increasing healthcare spending.
Who Are HXBM's Key Customers?
- Patients with skin and wound infections.
- Healthcare providers and dermatology clinics.
- Pharmaceutical and skincare companies through out-licensing agreements.
HXBM Financials
HXBM Latest News
No recent news available for HXBM.
HXBM Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HXBM.
Price Targets
Wall Street price target analysis for HXBM.
HXBM MoonshotScore
What does this score mean?
The MoonshotScore rates HXBM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Robin L. Carmichael
CEO
Robin L. Carmichael serves as the CEO of Helix BioMedix, Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries, with a focus on strategic leadership and business development. He has held various leadership positions in companies focused on drug development and commercialization. Carmichael's expertise lies in guiding companies through critical growth phases, securing partnerships, and driving innovation. His educational background includes advanced degrees in business and science, providing a strong foundation for leading a biotechnology company.
Track Record: Under Robin L. Carmichael's leadership, Helix BioMedix has focused on expanding its portfolio of bioactive peptides and strengthening its out-licensing strategy. Key achievements include securing partnerships with dermatology clinics and expanding the company's research and development efforts. Carmichael has also overseen the company's efforts to navigate regulatory challenges and secure patents for its proprietary technologies. His strategic decisions have aimed at positioning Helix BioMedix for long-term growth and profitability.
HXBM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Helix BioMedix may not meet the minimum financial standards required for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited reporting requirements and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier typically includes companies with higher risk profiles due to factors such as financial instability, limited operating history, or regulatory issues. Investing in companies on the OTC Other tier requires careful due diligence and an understanding of the associated risks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited liquidity due to OTC listing.
- Lack of financial transparency due to unknown disclosure status.
- Higher price volatility compared to major exchange-listed stocks.
- Potential for limited regulatory oversight.
- Risk of delisting or trading suspension.
- Verify the company's financial reporting status and access available financial statements.
- Assess the company's management team and their experience.
- Review the company's business plan and growth strategy.
- Evaluate the company's competitive landscape and market position.
- Analyze the company's capital structure and debt levels.
- Consult with a financial advisor to assess the risks and potential rewards.
- Check for any regulatory actions or legal issues involving the company.
- The company has been in operation since 1988.
- Focus on developing and commercializing bioactive peptides.
- Out-licensing agreements suggest potential value in their technology.
What Investors Ask About Helix BioMedix, Inc. (HXBM) — Healthcare
What does Helix BioMedix, Inc. do?
Helix BioMedix, Inc. is a specialty dermatology company that develops and commercializes bioactive peptides for various skin health applications. The company focuses on creating anti-infective, anti-fungal, and anti-inflammatory peptides used in treatments for skin and wound infections, as well as the prevention of staphylococcus aureus infections. In addition to its own product development, Helix BioMedix also out-licenses its proprietary peptides to other entities, expanding its market reach and revenue potential within the dermatology and biotechnology sectors.
What do analysts say about HXBM stock?
As of 2026-03-15, there is no available analyst coverage for Helix BioMedix, Inc. (HXBM). The company's small market capitalization and OTC listing may contribute to the lack of analyst coverage. Investors should conduct their own due diligence and consider the company's financial performance, growth prospects, and risk factors before making any investment decisions. Key metrics to consider include the company's gross margin, profit margin, and cash flow.
What are the main risks for HXBM?
The main risks for Helix BioMedix, Inc. include its small size, limited financial resources, and OTC market listing. The company faces competition from larger pharmaceutical and skincare companies, and its success depends on obtaining regulatory approvals for its new products. The lack of financial transparency due to the unknown disclosure status adds further risk. Investors should also consider the potential for limited liquidity and higher price volatility associated with OTC stocks. Dependence on key personnel and the potential need for additional funding are also significant risks for HXBM.
What are the key factors to evaluate for HXBM?
Helix BioMedix, Inc. (HXBM) currently holds an AI score of 50/100, indicating moderate score. Key strength: Proprietary peptide technologies. Primary risk to monitor: Failure to obtain regulatory approvals for new products. This is not financial advice.
How frequently does HXBM data refresh on this page?
HXBM prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven HXBM's recent stock price performance?
Recent price movement in Helix BioMedix, Inc. (HXBM) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary peptide technologies. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider HXBM overvalued or undervalued right now?
Determining whether Helix BioMedix, Inc. (HXBM) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying HXBM?
Before investing in Helix BioMedix, Inc. (HXBM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited financial data available for comprehensive analysis.
- OTC market listing introduces liquidity and regulatory risks.
- AI analysis pending for HXBM.